Etudes cliniques en cours

Découvrez ici la liste des différentes études cliniques en cours classées par centre.

CHU Liège

  • PDC –LUNG-101 : An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)
  • REALEC : A multicenter non-interventional cohort study to evaluate the realworld clinical management and outcomes of patients diagnosed with ALK-positive advanced NSCLC treated with ALECTINIB (REALEC)
  • MARIPOSA-2 : A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure)
  • CARMEN EFC158-58 : Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic nonsquamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors
  • CA001-050: A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
  • ETOP 13-18 BEAT-meso : A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma
  • Amgen 20190288 (ouverture mars 2022) : A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-Line Treatment (CodeBreaK 201)
  • AEGAN : A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
  • LUMINOSITY : A Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

CHU Mont-Godinne

Etudes sponsorisées interventionnelles en cours:

  • PEARLS: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.
  • Intr@pid: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer.

Etudes sponsorisées non interventionnelles en cours:

  • BEPACT Lung: Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study.

Etudes académiques non interventionnelles en cours:

  • ELCWP: Cardiovascular morbidities and lung cancer treatment: a prospective registry.

Cliniques Universitaires Saint-Luc

Etudes Onco en cours
1st line
BO29554 study (B-FAST)A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial)NSCLC (ROS+) A venir: BRAF V600+P.C
ADRIATIC (D933QC00001)Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT)SCLC limités post-chimioradioT.P
ANAM 17-21A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLCNSCLC cachexiaT.P
Zenith20 (Spectrum) (SPI-POZ-202)Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)NSCLC IV EGFR ou HER2 exon 20 inser/mutT.P
CA209-73LA Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC)NSCLC IIIA/B/CTP
2nd line
ImmunoSABRPhase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer NSCLC IVX.G
AMG510 (20190009)A Phase 3 Multicenter, Randomized, Open
Label, Active-controlled, Study of AMG 510
Versus Docetaxel for the Treatment of Previously
Treated Locally Advanced and Unresectable or
Metastatic NSCLC Subjects With Mutated KRAS
3rd line
ImmunoSABRPhase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer NSCLC IVX.G
EORTC: E2-Radiate 1811E²-RADIatE:
EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
Tous cancers oligométa traités par RthXG
PACIFIC R D4194R00005First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapyNSCLC stage III with durvalumab post chimioradioT.P
Immuno PoumonEtude prospective des facteurs pronostics et prédictifs de l'immunothérapie dans le cancer du poumonNSCLC FAb
SPECTAScreening Cancer Patients for Efficient Clinical Trial AccessNSCLC IV naïfs/ thymomes, mésothéliome IV naïfsT.P


PathologiesEtude - NomEtude -codeTitreEudractNCTPhasePI
Poumons et ThoraxANAM-17-21ANAM-17-21A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated
weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
2018-002927-40NCT03743064 Phase 3Colinet Benoît
Poumons et ThoraxCA001-050CA001-050A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerNCT04702880Phase 2Colinet Benoît
Poumons et ThoraxCodeBreaK 10020170543A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)2018-001400-11NCT03600883Phase 2Colinet Benoît
Poumons et ThoraxEXCLAIM-2TAK-788-3001Phase III clinical trial evaluating TAK-788 versus platinum-based chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) as first-line treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
2019-001845-42NCT04129502Phase 3Colinet Benoît
Poumons et ThoraxMARIPOSA73841937NSC3003 (Labcorp Project #: 210418)A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer – MARIPOSA2020-000743-31NCT04487080Phase 3Colinet Benoît
Poumons et ThoraxMK7684A-002MK7684A-002A Phase 2, Multi-center, Randomized Study to Compare the Efficacy and Safety of MK-7684A Or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With A Platinum Doublet Chemotherapy and Immunotherapy 2020-004034-38NCT04725188Phase 2Colinet Benoît
Poumons et ThoraxPACIFIC-4D9103C00001A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)2018-002572-41NCT03833154Phase 3Colinet Benoît
Poumons et ThoraxPDC-Lung-101PDC-Lung-101An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC) 2018-002382-19NCT03970746Phase 1aColinet Benoît
Poumons et ThoraxSAPPHIRE516-005A randomized phase 3 study of Sitravatinib in combination with Nivolumab versus Docetaxel in patients with advanced non-squamous non-small cell lung cancer with disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.2019-001043-41 NCT03906071Phase 3Canon Jean-Luc
Poumons et ThoraxSkyscraper 03GO41854A phase 3, open-label, randomized study of Atezolizumab and Tiragolumab compared with Durvalumab in patients with locally advanced, unresectable stage 3 non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation.2019-0044773-29NCT04513925Phase 3Colinet Benoît
Toutes Tumeurs DF1001-001 DF1001-001A phase I/II, first-in-human, multi-part, open-label, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of DF1001 in patients with locally advanced or metastatic solid tumors, and expansion in selected indications2019-004706-10NCT04143711Phase 2Canon Jean-Luc
Toutes TumeursBALLETTBSMO2020-2A study to examine the clinical value of comprehensive genomic profiling performed by Belgian NGS laboratories: a Belgian Precision study of the BSMO in collaboration with the Cancer Centre - Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT)NCT05058937Prospective-Collection d'échantillonsCanon Jean-Luc
Toutes TumeursPrecision 1 BSMO 2014-2The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment
NCT03873103Prospective-Collection d'échantillonsCanon Jean-Luc
Toutes TumeursPrecision 2 - Afatinib1200.264Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation followed by the addition of paclitaxel to afatinib at disease progression.2016-003411-34 NCT03810872Phase 2Canon Jean-Luc
Toutes TumeursPrecision 2 – Olaparib 1-2018 BSMOEfficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. SAUF SEIN, OVAIRE, PROSTATE, ATM gene
2018-002966-37 NCT03967938Phase 2Canon Jean-Luc
Toutes TumeursSGNTUC-019SGNTUC-019A phase 2 basket study of Tucatinib in combination with Trastuzumab in subjects with previously treated, locally advanced unresectable or metastatic solid tumors driven by HER2 alterationsNCT04579380Phase 2Canon Jean-Luc
Toutes TumeursTAPISTRYBO41932Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in patients with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by an next-generation-sequencing (NGS) assay2020-001847-16NCT04589845Phase 2Canon Jean-Luc


Connectez-vous pour avoir accès au contenu privé.

Nous utilisons des cookies sur notre site web. Certains d’entre eux sont essentiels au fonctionnement du site et d’autres nous aident à améliorer ce site et l’expérience utilisateur (cookies traceurs). Vous pouvez décider vous-même si vous autorisez ou non ces cookies. Merci de noter que, si vous les rejetez, vous risquez de ne pas pouvoir utiliser l’ensemble des fonctionnalités du site.